that sustained-release therapy integrates the advantages of chemotherapy and immunotherapy, and for the first time, the two have been combined and applied to intratumoral therapy through intervention. It integrates local and global treatment, and increases the concentration and time of drug action through sustained release of drugs within the tumor, which not only plays a local anticancer effect of chemotherapy drugs, but also takes into account the role of systemic immunotherapy, thus making up for the shortcomings of other therapies, providing new ideas and approaches for cancer treatment, especially for middle and advanced tumors, especially for reducing tumor recurrence and inhibiting tumor The transfer has very important value;this therapy was selected for "Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (7th edition) jointly formulated by the Chinese Anti-Cancer Association, the National Clinical Medical Research Center for Radiology and Therapy, and the National Interventional Medicine Innovation Alliance was published at Journal of Clinical Radiology, volume 43, number 19, 2024, 1636-1648.
MoreBaofa Yu, M.D. Chief Physician in China, Adjunct Professor at University of Texas (El Paso) (2016) and Adjunct Professor at Western University of Health Sciences (2016). He graduated from Peking Union Medical College (Peking Union Medical College) in 1988. He was a post-doctoral fellow at UCSD from 1990 to 1991, Salk from 1992 to 1993, Assistant Adjunct Professor, UCSD from 1994 to 1998. In the United States, he was mainly engaged in the research of cancer drug carrier drug delivery and tumor molecular biology. He invented the new concept of using tumor tissue as a sustained release system of anticancer drugs and the treatment method of sustained release reservoir, which has clinical application value, it is also called ultro-Minimum incision personalized intratumoral chemoimmunotherapy (UMIPIC).
Prof. Yu Topics